Lifeboat Foundation

That’s a good boy.

WEDNESDAY, Sept. 23, 2020 (HealthDay News) — A common type 2 diabetes drug called metformin may have an unexpected, but positive, side effect: New research suggests that people taking the drug appear to have significantly slower declines in thinking and memory as they age.

“Our six-year study of older Australians with type 2 diabetes has uncovered a link between metformin use and slower cognitive [mental] decline and lower dementia rates,” said study author Dr. Katherine Samaras. She’s the leader of the healthy aging research theme at the Garvan Institute of Medical Research in New South Wales, Australia.

“The findings provide new hope for a means of reducing the risk of dementia in individuals with type 2 diabetes, and potentially those without diabetes,” Samaras said.

On Sept. 29, we are launching science, tech demos, & products to the International Space Station!

🌱 Growing radishes in space
🧬 Cancer therapies
🚽 Space toilet
🌊 Water recovery
🎥 A Felix & Paul Studios Virtual Reality camera
💫 An Estee Lauder serum.

A Swedish company is developing technology that could allow truck drivers to work from home.
Al Jazeera’s Paul Rhys reports from Sandhult in southern Sweden.

- Subscribe to our channel: http://aje.io/AJSubscribe
- Follow us on Twitter: https://twitter.com/AJEnglish
- Find us on Facebook: https://www.facebook.com/aljazeera
- Check our website: https://www.aljazeera.com/

#AlJazeeraEnglish #Sweden #Coronavirus

The dramatic shift to online learning as a result of the COVID-19 pandemic risks widening educational inequalities.

Targeting Mechanisms of Aging Across Species — I am joined on this episode of ideaXme by Dr. Matt Kaeberlein, Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences, University of Washington, to discuss his research focus on cross-species mechanisms of aging, in order to facilitate interventions that extend healthspan and improve quality of life — #Ideaxme #Health #Wellness #Longevity #Aging #LifeExtension #Rapamycin #MTor #CElegans #ExtracellularVesicles #Geroscience #GenomicInstability #AlzheimersDisease #Neurodegeneration #Parkinsons #MitochondrialDysfunction #OralHealth #SystemsBiology #DogAgingProject #Science #Transhumanism #Innovation #Immortality #IraPastor #Bioquark #Regenerage The Dog Aging Project.

Ira Pastor, idea me life sciences ambassador and founder of Bioquark, interviews Dr. Matt Kaeberlein, Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington.

Continue reading “Targeting the Mechanisms of Aging Across Species” »

Software bugs are a tale as old as time — which, in the case of programming, means about 75 years. In 1947, programmer Grace Murray Hopper was working on a Mark II Computer at Harvard University when she noticed a moth that was stuck in the relay, preventing the computer program from running. It was the first “bug”, and countless others have followed since then.

In the history of programming, bugs have ranged from harmless to absolutely catastrophic. In 1986 and 1987, several patients were killed after a Therac-25 radiation therapy device malfunctioned due to an error by an inexperienced programmer, and a software bug might have also triggered one of the largest non-nuclear explosions in history, at a Soviet trans-Siberian gas pipeline.

While events such as this are rare, it’s safe to say that software bugs can do a lot of damage and waste a lot of time (and resources). According to recent analysis, the average programmer produces 70 bugs per 1,000 lines of code, with each bug demanding 30 times more time to fix than it took to write the code in the first place. In the US alone, an estimated $113 billion is spent identifying and fixing code bugs…

Summary: Metformin, a drug commonly used to treat diabetes, slows cognitive decline and reduces dementia risk in older people with diabetes.

Source: garvan institute of medical research.

Metformin is the first-line treatment for most cases of type 2 diabetes and one of the most commonly prescribed medications worldwide, with millions of individuals using it to optimise their blood glucose levels.

Toronto scientists have mapped the genes allowing cancer cells to avoid getting killed by the immune system in a finding that paves the way for the development of immunotherapies that would be effective for larger patient populations and across different tumour types.

“Over the last decade, different forms of immunotherapy have emerged as really potent cancer treatments but the reality is that they only generate durable responses in a fraction of patients and not for all tumour types,” says Jason Moffat, a professor of molecular genetics in the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto who led the work.

The study also revealed the need for new therapy to take into account the genetic composition of tumours because of mutations in the cancer cells that can potentially make the disease worse in response to treatment, often referred to as cancer resistance mutations.